ENDOTHELIAL PROTECTIVE EFFECT OF LIRAGLUTIDE IN TYPE 2 DIABETES MELLITUS

Background. Endothelial dysfunction underlies the development of chronic complications in type 2 diabetes mellitus. Glucose-lowering drugs with additional protective effects on endothelium are required. Objective. To study endothelial protective action of liraglutide in patients with type 2 diabetes mellitus and to detect its relation with glycemic control. Design and methods. The study was held in patients with type 2 diabetes mellitus with glycated hemoglobin 7,5–9,0 % who received metformin monotherapy. Metformin dose had been titrated for 3 months. Patients who reached glycated hemoglobin level less than 7,5 % were included in the group 1 — they had received metformin monotherapy for next 6 months. Patients with glycated hemoglobin over 7,5 % after 3 months formed the group 2, and they received liraglutide in addition to metformin for the following 6 months. At baseline, at 3, 6 and 9 months, endothelium-dependent vasodilation was evaluated by forearm microcirculation dopplerography with 0,3 % acetylcholine solution ionophoresis. Results. At baseline, patients of groups 1 and 2 showed impaired endothelium-dependent vasodilation (decrease of the reaction to acetylcholine, curve form change). There was no significant change in the linear blood flow parameters in the group 1 when euglycemia was reached by metformin monotherapy. Additional administration of liraglutide in the group 2 led to the increase in the amplitude and favourable change of the curve form. These changes were more prominent after 6 months of combined therapy. Endothelium-dependent vasodilation amplitude reached values observed in healthy subjects after 9 months from the study beginning. Conclusions. The improvement of glycemia control (euglycemia) does not have endothelial protective properties on its own. Liraglutide has its own endothelial protective action independent of glycemia control.

type 2 diabetes mellitus, endothelial dysfunction, endothelium-dependent vasodilation, glucagonlike peptide-1 receptor agonist, liraglutide

1. IDF Diabetes Atlas. 8th edition. 2017. Available from: http://www.diabetesatlas.org/across-the-globe.html

2. Li N, Zhao Y, Yue Y, Chen L, Yao Z, Niu W. Liraglutide ameliorates palmitate-induced endothelial dysfunction through activating AMPK and reversing leptin resistance. Biochem Biophys Res Commun. 2016;478(1):46–52. doi:10.1016/j.bbrc.2016. 07.095

3. Liu H, Dear AE, Knudsen LB, Simpson RW. A longacting glucagon-like peptide-1 analogue attenuates induction of plasminogen activator inhibitor type-1 and vascular adhesion molecules. J Endocrinol. 2009;201(1):59–66. doi:10.1677/JOE-08–0468

4. Koska J, Schwartz EA, Mullin MP, Schwenke DC, Reaven PD. Improvement of postprandial endothelial function after a single dose of exenatide in individuals with impaired glucose tolerance and recent-onset type 2 diabetes. Diabetes Care. 2010;33(5):1028–30. doi:10.2337/dc09–1961

5. Koska J, Sands M, Burciu C, D’Souza KM, Raravikar K, Liu J et al. Exenatide protects against glucose- and lipid-induced endothelial dysfunction: evidence for direct vasodilation effect of GLP-1 receptor agonists in humans. Diabetes. 2015;64(7):2624–35. doi:10.2337/db14–0976

6. Irace C, De Luca S, Shehaj E, Carallo C, Loprete A, Scavelli F et al. Exenatide improves endothelial function assessed by flow mediated dilation technique in subjects with type 2 diabetes: results from an observational research. Diab Vasc Dis Res. 2013;10 (1): 72–7. doi:10.1177/1479164112449562

7. Suzuki K, Tanaka S, Aoki C, Kato K, Jojima T, Aso Y. Greater efficacy and improved endothelial dysfunction in untreated type 2 diabetes with liraglutide versus sitagliptin. Dokkyo J Med Sci. 2014;41(3):211–220.

8. Kelly AS, Bergenstal RM, Gonzalez-Campoy JM, Katz H, Bank AJ. Effects of exenatide vs. metformin on endothelial function in obese patients with prediabetes: a randomized trial. Cardiovasc Diabetol. 2012;11:64. doi:10.1186/1475–2840–11–64

9. Nandy D, Johnson C, Basu R, Joyner M, Brett J, Svendsen CB et al. The effect of liraglutide on endothelial function in patients with type 2 diabetes. Diab Vasc Dis Res. 2014;11(6):419– 30. doi:10.1177/1479164114547358

10. Nomoto H, Miyoshi H, Furumoto T, Oba K, Tsutsui H, Miyoshi A et al. A сomparison of the effects of the GLP-1 analogue liraglutide and insulin glargine on endothelial function and metabolic parameters: a Randomized, Controlled Trial Sapporo Athero-Incretin Study 2 (SAIS2). PLoS One. 2015;10(8): e0135854. doi:10.1371/journal.pone.0135854

11. Forst T, Michelson G, Ratter F, Weber MM, Anders S, Mitry M et al. Addition of liraglutide in patients with type 2 diabetes well controlled on metformin monotherapy improves several markers of vascular function. Diabet Med. 2012;29 (9):1115–8. doi:10.1111/j.1464–5491.2012.03589.x

12. Ke J, Liu Y, Yang J, Lu R, Tian Q, Hou W et al. Synergistic effects of metformin with liraglutide against endothelial dysfunction through GLP-1 receptor and PKA signalling pathway. Sci Rep. 2017;7:41085. doi:10.1038/srep41085